Biotransformation
Because the threat of infectious diseases can cause widespread fear in a community, these diseases receive much public attention. Collaborations that bring together industry, academia, regulators, and the public can lead to improved and accelerated drug development. The collaborations must be ground...
Saved in:
| Published in: | Clinical pharmacology and therapeutics Vol. 96; no. 3; pp. 281 - 283 |
|---|---|
| Main Author: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Blackwell Publishing Ltd
01-09-2014
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Because the threat of infectious diseases can cause widespread fear in a community, these diseases receive much public attention. Collaborations that bring together industry, academia, regulators, and the public can lead to improved and accelerated drug development. The collaborations must be grounded in strong science and expertise in clinical trials. Development of drugs to treat infections caused by resistant bacteria, drugs to treat hepatitis C virus (HCV), and drugs to prevent HIV is taking advantage of these collaborations.
Clinical Pharmacology & Therapeutics (2014); 96 3, 281–283. doi:10.1038/clpt.2014.133 |
|---|---|
| Bibliography: | ark:/67375/WNG-WQBTV3QN-Z ArticleID:CPTCLPT2014133 istex:EB3FDF7D0DBCDF635A330E1609EF350080395BA7 |
| ISSN: | 0009-9236 1532-6535 |
| DOI: | 10.1038/clpt.2014.133 |